HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
Company profile
Ticker
BEAT, BEATW
Exchange
Website
CEO
Mr. Robert P. Eno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Columbia Care Inc.
SEC CIK
Corporate docs
IRS number
474881450
BEAT stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
7 Nov 24
8-K
HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
22 Oct 24
8-K
HeartBeam Names Timothy Cruickshank as Chief Financial Officer
10 Sep 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
424B5
Prospectus supplement for primary offering
3 May 24
8-K
Entry into a Material Definitive Agreement
2 May 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
Transcripts
BEAT
Earnings call transcript
2024 Q3
7 Nov 24
BEAT
Earnings call transcript
2024 Q2
14 Aug 24
BEAT
Earnings call transcript
2024 Q1
9 May 24
BEAT
Earnings call transcript
2023 Q4
20 Mar 24
BEAT
Earnings call transcript
2023 Q3
14 Nov 23
BEAT
Earnings call transcript
2023 Q2
10 Aug 23
BEAT
Earnings call transcript
2023 Q2
10 Aug 23
BEAT
Earnings call transcript
2023 Q1
11 May 23
BEAT
Earnings call transcript
2022 Q4
16 Mar 23
BEAT
Earnings call transcript
2022 Q3
10 Nov 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.82 mm | 5.82 mm | 5.82 mm | 5.82 mm | 5.82 mm | 5.82 mm |
Cash burn (monthly) | 1.13 mm | 1.12 mm | 1.69 mm | 1.59 mm | 1.10 mm | 1.10 mm |
Cash used (since last report) | 1.50 mm | 1.49 mm | 2.25 mm | 2.11 mm | 1.47 mm | 1.46 mm |
Cash remaining | 4.32 mm | 4.34 mm | 3.57 mm | 3.71 mm | 4.36 mm | 4.36 mm |
Runway (months of cash) | 3.8 | 3.9 | 2.1 | 2.3 | 4.0 | 4.0 |
Institutional ownership, Q2 2024
29.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 7 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 5.80 bn |
Total shares | 7.82 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Strome Mark E | 2.90 mm | $6.50 mm |
Public Ventures | 2.62 mm | $0.00 |
Vanguard | 713.85 k | $1.83 bn |
Smith, Salley & Associates | 250.00 k | $642.50 mm |
Geode Capital Management | 213.09 k | $547.78 mm |
UBS UBS | 160.00 k | $411.21 mm |
Beacon Pointe Advisors | 133.33 k | $342.67 mm |
Spectrum Asset Management | 107.20 k | $275.50 mm |
SF Stifel Financial | 100.00 k | $257.00 mm |
Kestra Private Wealth Services | 91.02 k | $233.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Sep 24 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.34 | 1,674 | 3.92 k | 57,146 |
30 Aug 24 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.31 | 5,500 | 12.71 k | 58,820 |
27 Aug 24 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.26 | 2,194 | 4.96 k | 64,320 |
26 Aug 24 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.38 | 300 | 714.00 | 66,514 |
23 Aug 24 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.3 | 2,500 | 5.75 k | 66,814 |
Press releases
HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time
31 Oct 24
HeartBeam Named "Rising Star" at the 6th Annual Digital Health Hub Foundation Awards
24 Oct 24
Lifesaving Portable, AI Augmented Cardiac Monitoring Technology Poised for Commercial Launch Under New Industry Leader CEO: Heartbeam, Inc. (NASDAQ: BEAT)
17 Oct 24
HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
17 Oct 24
HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist
24 Sep 24